iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan ‐L‐ CN study
Authors' conclusion
The findings of this post hoc analysis suggest that iGlarLixi had greater benefits than iGlar in reducing the rate of residual hyperglycaemia over 30 weeks in Chinese people with suboptimally controlled T2D on prior BI-based therapy.
Study context
- Population
- Chinese people with uncontrolled T2D on prior basal insulin ± oral antidiabetic drugs124 with baseline residual hyperglycaemia
- Participants
- 421 people
- Comparison
- iGlarLixi vs iGlar
- Primary endpoint
- Residual hyperglycaemia (HbA1c ≥ 7.0% and FPG < 7.0 mmol/L)
- Follow-up
- Over 30 weeks
Primary result
As reported in the abstract
Residual hyperglycaemia rate · week 30
Further findings
Baseline residual hyperglycaemia
Both HbA1c and FPG targets achieved (subgroup with baseline residual hyperglycaemia) · week 30
| Outcome | Estimate | P value |
|---|---|---|
| Change in HbA1c (subgroup with baseline residual hyperglycaemia) · week 30−9.4 mmol/mol | LSM difference −0.9 % | P < 0.001 |
| Change in 2-hour PPG (subgroup with baseline residual hyperglycaemia) · week 30 | LSM difference −4.7 mmol/L | P < 0.001 |
- Baseline residual hyperglycaemia: overall 124 (29.5%)
Daily basal insulin dose · week 30
- Daily basal insulin (BI) dose similar in the two groups
Safety
- Incidence of hypoglycaemia similar in the two groups
Original publication
iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan ‐L‐ CN study. Diabetes Obes Metab. Published 3 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →